



COMPANY ANNOUNCEMENT

6 April 2022

No. 07-2022 – Inside information

ViroGates announces clinical routine use in Portugal

BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that the distribution partner in Portugal, Arium, has started successfully selling suPARnostic® to hospitals in the Portuguese market. The hospitals primarily use suPARnostic® to guide anakinra treatment in adult COVID-19 patients.

ViroGates supplies products to Arium on a centralized basis and cannot inform about the details of the individual accounts.

Jakob Knudsen, CEO of ViroGates, says: *“We are happy to see the first clinical customers in Portugal. This is a direct result of the recent EMA approval and Arium’s efforts to increase awareness about the benefits of suPAR in the Portuguese market. We are happy that Portuguese COVID-19 patients now also have access to suPAR-guided anakinra treatment. We expect to continue adding more clinical routine customers in Portugal and shift the use towards more general triage in emergency departments going forward.”*

The announcement can be found at
<https://www.virogates.com/investor/announcements>.

For further information, please contact:

ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.